Lundbeck hunts for new success drugs in niche diseases

Following a large reorganization of Lundbeck's R&D department, Lundbeck is ready to lift the veil on its future focus areas.

Lundbeck EVP and Head of R&D Johan Luthmann | Photo: PR / Lundbeck

The industry has seen it coming for some time, but in its most recent fiscal report, Lundbeck establishes: The Danish pharmaceutical company will be targeting niches in neurology and psychiatry going forward.

The firm is ready to shelve its large, broad indications – to a certain extent. As indicated in the annual report, the firm plans to focus on niches in neurology and psychiatry, or on rare neurological diseases, Lundbeck's Executive Vice President and Head of Research & Development Johan Luthman tells MedWatch after a year of reorganizations in his department.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs